MX9707944A - Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos. - Google Patents

Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos.

Info

Publication number
MX9707944A
MX9707944A MX9707944A MX9707944A MX9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A MX 9707944 A MX9707944 A MX 9707944A
Authority
MX
Mexico
Prior art keywords
methods
compositions
immunogenic
making
oligosaccharide
Prior art date
Application number
MX9707944A
Other languages
English (en)
Spanish (es)
Inventor
Andrew J Malcolm
Original Assignee
Alberta Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/477,497 external-priority patent/US5866132A/en
Priority claimed from US08/482,626 external-priority patent/US5695768A/en
Priority claimed from CA002153733A external-priority patent/CA2153733A1/en
Priority claimed from CA002153730A external-priority patent/CA2153730A1/en
Application filed by Alberta Res Council filed Critical Alberta Res Council
Publication of MX9707944A publication Critical patent/MX9707944A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX9707944A 1995-06-07 1997-10-15 Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos. MX9707944A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/477,497 US5866132A (en) 1995-06-07 1995-06-07 Immunogenic oligosaccharide compositions
US08/482,626 US5695768A (en) 1995-06-07 1995-06-07 Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
CA002153733A CA2153733A1 (en) 1995-07-12 1995-07-12 Immunogenic oligosaccharide compositions
CA002153730A CA2153730A1 (en) 1995-07-12 1995-07-12 Immunostimulating activity of streptococcus pneumoniae serotype 8 oligosaccharides

Publications (1)

Publication Number Publication Date
MX9707944A true MX9707944A (es) 1998-06-30

Family

ID=27427244

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707944A MX9707944A (es) 1995-06-07 1997-10-15 Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos.

Country Status (10)

Country Link
EP (1) EP0831894A1 (ja)
JP (1) JPH11506110A (ja)
KR (1) KR19990007777A (ja)
AU (1) AU725279B2 (ja)
CZ (1) CZ327897A3 (ja)
IL (1) IL121585A0 (ja)
MX (1) MX9707944A (ja)
NO (1) NO974727L (ja)
NZ (1) NZ309713A (ja)
WO (1) WO1996040225A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE208629T1 (de) 1996-08-27 2001-11-15 Chiron Corp Neisseria meningitidis serogruppe b glykokonjugate und verfahren zu deren verwendung
PL338146A1 (en) * 1997-07-17 2000-09-25 North American Vaccine Immunogenic complex combinations consisting of meningococcal porine of b group and h. influenzae polysaccharide
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU760669B2 (en) 1998-04-28 2003-05-22 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
CA2413450C (en) * 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
SG10201406432RA (en) * 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
EP2870974A1 (en) * 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
KR102480429B1 (ko) * 2014-09-26 2022-12-21 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 스트렙토코커스 뉴모니에 혈청형 8에 대한 백신
EP3000820A1 (en) * 2014-09-26 2016-03-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic vaccines against Streptococcus pneumoniae serotype 8
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
CN109890415B (zh) 2016-08-05 2023-04-04 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
CN109862908B (zh) 2016-08-05 2023-05-02 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN111050794A (zh) * 2017-09-07 2020-04-21 默沙东公司 将肺炎球菌多糖与载体蛋白缀合的配制方法
JP6950099B2 (ja) 2018-02-05 2021-10-13 サノフィ パスツール インコーポレイティッド 多価肺炎球菌多糖体−タンパク質複合体組成物
SG11202006387QA (en) 2018-02-05 2020-07-29 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3782642A4 (en) 2018-04-18 2022-04-13 SK Bioscience Co., Ltd. CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF
CA3120922A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
CN113607939A (zh) * 2021-08-05 2021-11-05 艾美探索者生命科学研发有限公司 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
EP0302887B1 (en) * 1986-04-16 1994-06-22 The Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines, and methods of manufacture
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
EP0567452B1 (en) * 1990-12-18 1996-05-15 The Board Of Regents Of The University Of Washington Dialysate production system with dialysate pellets
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine

Also Published As

Publication number Publication date
NZ309713A (en) 1999-11-29
NO974727L (no) 1997-12-08
KR19990007777A (ko) 1999-01-25
NO974727D0 (no) 1997-10-13
JPH11506110A (ja) 1999-06-02
AU725279B2 (en) 2000-10-12
IL121585A0 (en) 1998-02-08
EP0831894A1 (en) 1998-04-01
CZ327897A3 (cs) 1998-02-18
WO1996040225A1 (en) 1996-12-19
AU5994496A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
MX9707944A (es) Composiciones de oligosacaridos inmunigenicos e inmunoestimulatorios y metodos para fabricarlos y utilizarlos.
AU8483391A (en) Improved oligosaccharide conjugate vaccines
GR3035081T3 (en) Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
GB9713156D0 (en) Vaccines
WO2000056360A3 (en) Vaccine against antigens from bacteriae
ES8707861A1 (es) Un metodo para preparar un conjugado inmunogeno
WO1999055730A3 (en) Polyepitope carrier protein
AU3065489A (en) T-cell epitope as carriers molecule for conjugate vaccines
HK1041825A1 (en) A polysaccharide-protein conjugate or oligosaccharide-protein conjugate, a method for producing the same, and its uses thereof
EP0866133A3 (en) A group b streptococcus vaccine
WO2001037863A3 (en) Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen
HUT50048A (en) Process for producing streptococcus protein antigen and pharmaceutical compositions comprising same
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
WO1999052548A3 (en) Conjugate vaccines for the prevention of dental caries
CA2139217A1 (en) Vaccine composition for eliciting an immune response against n-glycolylated gangliosides and its use for cancer treatment
NZ331557A (en) Porphyromonas gingivalis antigens for the diagnosis and treatment of periodontitis
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
NZ500151A (en) A general method for attaching DNA molecule comprising non-antibody target molecule (eg. CTLA-4 or L-selectin), antigen or epitope sequence, and optionally a polypeptide sequence
AU3991899A (en) Verotoxin b subunit for immunization
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
Michon et al. Combination conjugate vaccines against multiple serotypes of group B streptococci
AU2579600A (en) Product and method for obtaining specific immunisation with one or more antigens
ES2092960A1 (es) Gen de la proteina 1 de union a transferrina (tbp1) de actinobacillus pleuropneumoniae, utilizacion de esta en la preparacion de productos para la vacunacion contra la pleuroneumonia y en reactivos de diagnostico.
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees